These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 15838425)

  • 21. Antitumor effects and normal-tissue toxicity of 111In-nuclear localization sequence-trastuzumab in athymic mice bearing HER-positive human breast cancer xenografts.
    Costantini DL; McLarty K; Lee H; Done SJ; Vallis KA; Reilly RM
    J Nucl Med; 2010 Jul; 51(7):1084-91. PubMed ID: 20554744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The level of insulin growth factor-1 receptor expression is directly correlated with the tumor uptake of (111)In-IGF-1(E3R) in vivo and the clonogenic survival of breast cancer cells exposed in vitro to trastuzumab (Herceptin).
    Cornelissen B; McLarty K; Kersemans V; Reilly RM
    Nucl Med Biol; 2008 Aug; 35(6):645-53. PubMed ID: 18678349
    [TBL] [Abstract][Full Text] [Related]  

  • 23.
    Kwon LY; Scollard DA; Reilly RM
    Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
    Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
    PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT.
    Chan C; Scollard DA; McLarty K; Smith S; Reilly RM
    EJNMMI Res; 2011 Aug; 1(1):15. PubMed ID: 22214307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Imaging and biodistribution of Her2/neu expression in non-small cell lung cancer xenografts with Cu-labeled trastuzumab PET.
    Paudyal P; Paudyal B; Hanaoka H; Oriuchi N; Iida Y; Yoshioka H; Tominaga H; Watanabe S; Watanabe S; Ishioka NS; Endo K
    Cancer Sci; 2010 Apr; 101(4):1045-50. PubMed ID: 20219072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
    McKnight BN; Viola-Villegas NT
    Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
    Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting of HER2-expressing tumors with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-terminally engineered cysteine.
    Ahlgren S; Wållberg H; Tran TA; Widström C; Hjertman M; Abrahmsén L; Berndorff D; Dinkelborg LM; Cyr JE; Feldwisch J; Orlova A; Tolmachev V
    J Nucl Med; 2009 May; 50(5):781-9. PubMed ID: 19372467
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An improved
    Khodadust F; Ahmadpour S; Aligholikhamseh N; Abedi SM; Hosseinimehr SJ
    Eur J Med Chem; 2018 Jan; 144():767-773. PubMed ID: 29291444
    [TBL] [Abstract][Full Text] [Related]  

  • 31. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of the anti-HER2 C6.5 diabody as a PET radiotracer to monitor HER2 status and predict response to trastuzumab treatment.
    Reddy S; Shaller CC; Doss M; Shchaveleva I; Marks JD; Yu JQ; Robinson MK
    Clin Cancer Res; 2011 Mar; 17(6):1509-20. PubMed ID: 21177408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of [
    Pougoue Ketchemen J; Njotu FN; Babeker H; Ahenkorah S; Tikum AF; Nwangele E; Henning N; Cleeren F; Fonge H
    Eur J Nucl Med Mol Imaging; 2024 Jun; 51(7):2070-2084. PubMed ID: 38376808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preclinical characterisation of 111In-DTPA-trastuzumab.
    Lub-de Hooge MN; Kosterink JG; Perik PJ; Nijnuis H; Tran L; Bart J; Suurmeijer AJ; de Jong S; Jager PL; de Vries EG
    Br J Pharmacol; 2004 Sep; 143(1):99-106. PubMed ID: 15289297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of intraoperative detection of tumor margins in patients with HER2-positive carcinoma of the breast following administration of 111In-DTPA-trastuzumab Fab fragments.
    Holloway CM; Scollard DA; Caldwell CB; Ehrlich L; Kahn HJ; Reilly RM
    Nucl Med Biol; 2013 Jul; 40(5):630-7. PubMed ID: 23618841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HER2-targeted dual radiotracer approach with clinical potential for noninvasive imaging of trastuzumab-resistance caused by epitope masking.
    Li L; Liu T; Shi L; Zhang X; Guo X; Hu B; Yao M; Zhu H; Yang Z; Jia B; Wang F
    Theranostics; 2022; 12(12):5551-5563. PubMed ID: 35910795
    [No Abstract]   [Full Text] [Related]  

  • 37. Growth inhibition of breast cancer cell lines overexpressing Her2/neu by a novel internalized fully human Fab antibody fragment.
    Belimezi MM; Papanastassiou D; Merkouri E; Baxevanis CN; Mamalaki A
    Cancer Immunol Immunother; 2006 Sep; 55(9):1091-9. PubMed ID: 16311733
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    Ahmadpour S; Noaparast Z; Abedi SM; Hosseinimehr SJ
    J Biomed Sci; 2018 Feb; 25(1):17. PubMed ID: 29455647
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Active targeting of block copolymer micelles with trastuzumab Fab fragments and nuclear localization signal leads to increased tumor uptake and nuclear localization in HER2-overexpressing xenografts.
    Hoang B; Ekdawi SN; Reilly RM; Allen C
    Mol Pharm; 2013 Nov; 10(11):4229-41. PubMed ID: 24066900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
    Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.